For example, genomic mutations that lead to amplification or ‘rewiring’ of key signalling pathways have been linked to failure of targeted therapies [5, 6]; however, co-targeting of these pathways has to date still failed to yield durable KRAS-mutant CRC treatments [7–10]. Here, KRAS is linked to colorectal carcinoma.